Thelansis

 Richter's syndrome (RS) is a highly aggressive transformation of chronic lymphocytic leukemia (CLL), often into diffuse large B-cell lymphoma (DLBCL). Its prognosis is grim, with only about a 20% complete remission rate and less than 20% long-term survival with chemoimmunotherapy (CIT). RS is biologically diverse, typically arising in patients with CLL, and certain high-risk genomic factors, such as unmutated IGHV status, NOTCH1 mutations, TP53 issues, and del11q, increase the risk of this transformation. Symptoms of Richter's Syndrome mainly involve sudden and painless swelling of lymph nodes in the neck, axilla, abdomen (usually the spleen), and groin. Patients often experience rapid unexplained weight loss, fever, and night sweats, collectively known as 'B-symptoms.' The standard first-line treatment is immuno-chemotherapy, combining chemodrugs with a targeted anti-CD 20 monoclonal antibody. Second-line chemotherapy regimens like R-ICE, D-HAC, R-DHAP, and GIVE may b...

 Richter's syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). ·        Richter's syndrome (RS) affects approximately 2-10% of patients with a prior diagnosis of CLL/SL. Thelansis’s “Richter’s Syndrome (RS) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Richter’s Syndrome (RS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Richter’s Syndrome (RS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around cu...